Online inquiry

IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4072MR)

This product GTTS-WQ4072MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGF1&IGF2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000618.5; NM_000612.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3479; 3481
UniProt ID P05019; P01344
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4072MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ368MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ10471MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY2541546
GTTS-WQ13033MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ10338MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY 3090106
GTTS-WQ7619MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEN1029
GTTS-WQ7125MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FE 999302
GTTS-WQ15939MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ3190MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ARENEGYR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW